Cambrex Completes Expansion and Manufacturing Capability Upgrades in Milan

News
Article

The expansion includes a new R&D laboratory and the installation of a 12,000-liter reactor at one of the company’s manufacturing facilities on its Paullo site in Milan, Italy.

Cambrex, a small-molecule company providing drug substance, drug product, and analytical services across the drug lifecycle, announced on March 14, 2019 that it has completed the expansion of a new 150-mR&D laboratory at its site in Paullo, Milan, Italy.

The R&D laboratory includes both chemistry and analytical development capabilities, with the installation of semi-automated glass-lined reactors as well as analytical instruments, including multiple high- and ultra-performance liquid chromatography, as well as gas chromatography systems, which have now been qualified and validated, the company reports. To complement investments at other Cambrex sites, the new laboratory has also installed a flow chemistry system to allow for continuous manufacturing development.

Additionally, the company has installed a new 12,000-liter reactor into one of its cGMP manufacturing facilities at the site. The installation of the reactor, along with the replacement of centrifuges with new equipment in one of the site’s seven production departments, is part of a $3-million investment to upgrade and improve the efficiency of the plant, which manufactures intermediates and generic APIs under GMP conditions.

“This investment is part of our ongoing strategy to ensure that the site can adapt to the growing and evolving needs of the generic API industry,” said Aldo Magnini, managing director, Cambrex Milan, in a company press release. “Investing in key technologies such as continuous flow will allow us to look at new opportunities for the site to expand our portfolio of generic products, in a similar manner to the investment in highly potent API containment that we undertook in 2017, which allowed us to increase the number of new highly-potent oncology products in development.”

Source: Cambrex

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content